Clinic Roundup

 Biotie Therapies Oyj, of Turku, Finland, said it completed enrollment in its Phase IIb trial testing tozadenant in Parkinson's disease and expects top-line data to be available around the end of the year. The 420-patient study is designed to determine the efficacy of the selective adenosine 2A receptor inhibitor in reducing the mean number of hours per day patients spend in the "off" state.